Newtopia Reports First Quarter 2023 Financial Results

News provided by

May 30, 2023, 16:30 ET

Ongoing cost optimization to achieve profitability in 2023
Q1 2023 gross margin (non IFRS)¹ up 1300 basis points year over year
Quarterly conference call scheduled for May 30, 2023 at 5 pm ET

TORONTO, May 30, 2023 /PRNewswire/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, today announced its first quarter financial results, operational highlights and filing of quarterly financial statements. These results pertain to the three months ended March 31, 2023. All amounts are expressed in Canadian dollars, unless otherwise noted.

First Quarter 2023 Financial Highlights (vs. Q1 2022):

Revenue of $2.65 million, as compared to $2.87 million.
Gross profit margin¹of 60%, as compared to 47%.

"We continued to see momentum in gross profit and operating expense improvements in the first quarter as we implement the strategic plan we laid out in 2022," said Jeff Ruby, Founder and CEO of Newtopia. "We are actively managing our expenses to achieve profitability in 2023, and our goal of reducing expenses is quickly coming to fruition. For the first quarter, gross profit margins increased 1300 basis points year-over-year. This ramp in expense cuts will continue throughout the year as we make our way toward EBITDA and cash flow positive."

Ruby continued, "We look forward to seeing the benefit of several recent multi-year contract renewals with large clients that will further enhance our revenue and profitability in the second half of the year. As a result of implementing one of these multi-year contract renewals for a large client during the quarter, we identified hundreds of participants who had made material health improvements using our platform, providing further evidence that our solution is highly engaging and effective. For this group, we made some important value-based changes to our definition of engaged participants that we intend to further improve their habits. While this change had a declining impact on our first quarter revenue, we anticipate that we will be able to adjust to this higher engagement level commitment in successive quarters as we transition additional participant engagement behaviors into habits.

In addition to organic growth, our pipeline of new business with self-insured employers and innovative health plans remains robust. Opportunities from leading macro drivers for our industry, including the growing popularity of, and commercial interest in, GLP-1 medications for diabetes and weight management, alongside growth in advanced primary care are creating a vast new landscape of possibilities for habit change platforms like Newtopia. I continue to believe that there is no better time to invest in primary prevention habit change, and Newtopia is at the forefront of preventing, reversing and slowing chronic disease."

First Quarter 2023 Financial Results

Revenue for the three months ended March 31, 2023 was $2.65 million, compared to $2.87 million in the prior-year period. Enrollment fee revenue, or revenue from Welcome Kit sales, totaled 19% of revenue for the quarter.

Non-IFRS gross profit for the first quarter 2023 totaled $1.6 million, as compared to $1.3 million in the prior-year period. This calculation is comprised of Newtopia's revenue less direct expenses, which include the cost of Welcome Kits sold to new participants and labor costs associated with hiring and training the Company's coaching team of Inspirators. As a percentage of revenue, gross profit totaled 60%, compared to 47% in the prior-year period.

Operating expenses² for the three months ended March 31, 2023 totaled $2.3 million, compared to $2.6 million in the prior-year period. For the first quarter, EBITDA³ totaled a loss of $0.7 million, compared with $1.2 million in the prior-year period.

The Company ended the first quarter 2023 with approximately $0.3 million in cash, with additional access to its revolving line of credit with a Canadian Schedule 1 bank.

2023 Outlook

Newtopia continues to anticipate top and bottom-line year-over-year growth in 2023. In addition, due to continued strategic expense management including additional cuts made in the first quarter, Newtopia anticipates that the Company is currently on a clear path to EBITDA and cash flow positive within 2023. Profitability is anticipated to build throughout the year, with the bottom line improving incrementally each quarter.

Conference Call

The Company will host a conference call today at 5 p.m. Eastern Time to discuss the first quarter 2023 results in further detail. To access the conference call, please dial (877) 407-3982 (U.S.) or (201) 493-6780 (International) 10 minutes prior to the start time and reference Conference ID number . The call will also be available via live webcast on the investor relations portion of the Company's website located at investor.newtopia.com.

A replay of the conference call will be available through June 13, 2023 which can be accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International) and entering the passcode 13738818. The webcast will also be archived on the Company's website.

About Newtopia

Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for health insurers. As a provider of whole person care, we prevent, reverse and slow the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social and behavioral insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. To learn more, visit newtopia.com , LinkedIn or Twitter.

Forward Looking Statements

This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable United States securities legislation (collectively, "forward-looking statements"), which reflects management's expectations regarding Newtopia's future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. All statements other than statements of historical fact may be forward- looking information. Such statements reflect Newtopia's current views and intentions with respect to future events, based on information available to Newtopia, and are subject to certain risks, uncertainties, and assumptions. Material factors or assumptions were applied in providing forward-looking information. While forward-looking statements are based on data, assumptions and analyses that Newtopia believes are reasonable under the circumstances, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Forward-looking statements are not a guarantee and are based on a number of estimates and assumptions management believes to be relevant and reasonable, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Certain of the "risk factors" that could cause actual results to differ materially from Newtopia's forward-looking statements in this press release include, without limitation: the termination of contracts by clients, risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters- in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in Newtopia's disclosure documents, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com including Newtopia's final long form prospectus dated March 30, 2020.

Should any factor affect Newtopia's in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Non-IFRS Financial Measures

The Company's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). Management uses certain non-IFRS measures, which are defined in the appropriate sections of this press release, to better assess the Company's underlying performance. These measures are reviewed regularly by management and the Company's Board of Directors in assessing the Company's performance and in making decisions about ongoing operations. In addition, we use certain non-IFRS measures to determine the components of management compensation. We believe that these measures are also used by investors as an indicator of the Company's operating performance. Readers are cautioned that these terms are not recognized IFRS measures and do not have a standardized meaning under IFRS and should not be construed as alternatives to IFRS terms, such as net income.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Key Financial Measures and Schedule of Non-GAAP Reconciliations

Gross Profit Information ^[1]

	Three Months Ended March 31,
	2023	2022
	$	$
Revenue	2,648,657	2,866,714
Cost of revenue	(1,275,682)	(1,517,836)
Gross profit	1,372,975	1,348,878
Add amortization of intangible asset	206,514	-
Non-IFRS adjusted gross profit	1,579,489	1,348,878

Gross profit margin	52 %	47 %
Non-IFRS adjusted gross profit margin	60 %	47 %

Reconciliation of Total Operating Expenses to Adjusted Operating Expenses ^[2]

	Three Months Ended March 31,
	2023	2022
	$	$
Total expenses	2,745,802	2,976,571
Add (Subtract)
Share-based compensation	(93,290)	(132,508)
Depreciation of property and equipment	(1,549)	(14,380)
Depreciation of right-of-use asset	-	(46,195)
Interest on lease obligations	(12,590)	(22,979)
Interest and accretion expense	(169,695)	(97,290)
Finance charges	(109,648)	(37,110)
Capitalized borrowing costs	-	29,000
Foreign exchange loss	(18,272)	(15,033)
Amortization of deferred finance charges	(33,815)	(58,800)

Adjusted operating expenses	2,306,943	2,581,276

EBITDA ^[3]

	Three Months Ended March 31,
	2023	2022
	$	$
Non-IFRS gross profit	1,579,489	1,348,878
Adjusted operating expenses	(2,306,943)	(2,581,276)

EBITDA	(727,454)	(1,232,398)

NEWTOPIA INC.
Condensed Interim Statements of Financial Position (Unaudited)
As at March 31, 2023 and December 31, 2022
(Expressed in Canadian Dollars)

	March 31,	December 31,
	2023	2022
	(Unaudited)	(Audited)
	$	$
Assets
Current assets
Cash	338,370	345,950
Trade and other receivables	1,469,887	1,557,640
Contract asset	55,400	190,000
Prepaid expenses and deposits	183,731	205,843
Inventories	214,976	325,571
Deferred costs	56,954	76,269
	2,319,318	2,701,273
Property and equipment	7,602	8,052
Intangible asset	3,028,849	3,235,363
	5,355,769	5,944,688
Liabilities
Current liabilities
Trade and other payables	2,320,039	2,584,039
Credit facility	4,434,191	4,823,545
Lease obligations	307,915	544,700
Deferred revenue	48,185	48,185
Debentures	2,456,046	2,409,103

	9,566,376	10,409,572

Debentures	1,096,749	1,068,772
	10,663,125	11,478,344
Equity/Deficit
Common shares	48,882,767	47,978,992
Contributed surplus	13,556,801	12,861,449
Deficit	(67,746,924)	(66,374,097)
	(5,307,356)	(5,533,656)
	5,355,769	5,944,688

NEWTOPIA INC.
Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited)
Three Months Ended March 31, 2023 and 2022
(Expressed in Canadian Dollars)

	2023	2022

	$	$

Revenue	2,648,657	2,866,714
Cost of revenue	1,275,682	1,517,836
Gross profit	1,372,975	1,348,878

Operating expenses
Technology and development	922,065	806,295
Sales and marketing	426,170	644,211
General and administrative	958,708	1,130,770
Share–based compensation	93,290	132,508
Depreciation of property and equipment	1,549	14,380
Depreciation of right–of–use asset	–	46,195
	2,401,782	2,774,359
Other expenses (income)
Interest on lease obligations	12,590	22,979
Interest and accretion expense	169,695	97,290
Finance charges	109,648	37,110
Capitalized borrowing costs	–	(29,000)
Foreign exchange loss	18,272	15,033
Amortization of deferred finance charges	33,815	58,800
	344,020	202,212

Net loss and comprehensive loss	(1,372,827)	(1,627,693)

NEWTOPIA INC.
Condensed Interim Statements of Changes in Equity (Unaudited)
Three Months Ended March 31, 2023 and 2022
(Expressed in Canadian Dollars)

	Common Shares	Contributed Surplus	Deficit	Total
	$	$	$	$
Balance, December 31, 2022	47,978,992	12,861,449	(66,374,097)	(5,533,656)
Net loss and comprehensive loss	–	–	(1,372,827)	(1,372,827)
Share–based compensation	–	93,290	–	93,290
Settlement of related party payable	–	38,542	–	38,542
Private placement offering of Units, net of issuance costs	930,218	537,077	–	1,467,295
Compensation options	(26,443)	26,443	–	-
Balance, March 31, 2023	48,882,767	13,556,801	(67,746,924)	(5,307,356)

Balance, December 31, 2021	45,177,120	11,652,200	(58,673,634)	(1,844,314)
Net loss and comprehensive loss	–	–	(1,627,693)	(1,627,693)
Share–based compensation	–	132,508	–	132,508
Settlement of related party payable	–	23,485	–	23,485
Balance, March 31, 2022	45,177,120	11,808,193	(60,301,327)	(3,316,014)

Condensed Interim Statements of Cash Flows (Unaudited)
Three Months Ended March 31, 2023 and 2022
(Expressed in Canadian Dollars)

	2023	2022
	$	$
Cash flows used in operating activities
Net loss and comprehensive loss	(1,372,827)	(1,627,693)
Items not involving cash:
Depreciation of property and equipment	1,549	14,380
Depreciation of right–of–use asset	–	46,195
Amortization of intangible asset	206,514	–
Capitalized borrowing costs	–	(29,000)
Amortization of deferred finance charges	33,815	58,800
Accretion expense	74,920	46,390
Interest on lease obligations	12,590	22,979
Stock–based compensation	93,290	132,508
	(950,149)	(1,335,441)
Change in non–cash working capital
Trade and other receivables	87,753	(190,564)
Prepaid expenses and deposits	22,112	74,638
Inventories	110,595	(68,233)
Trade and other payables	(225,458)	668,722
Contract asset/liability	134,600	137,554
Deferred revenue	–	(4,582)
	(820,547)	(717,906)
Cash flows used in investing activities
Purchase of property and equipment	(1,099)	(1,788)
Intangible asset development costs	–	(448,099)
	(1,099)	(449,887)
Cash flows provided by financing activities:
Credit facility withdrawals	1,415,546	2,318,568
Credit facility repayments	(1,804,900)	(804,580)
Credit facility financing costs	(14,500)	(15,381)
Repayment of lease obligations	(249,375)	(93,971)
Proceeds from private placement offering of Units, net of cash issuance costs	1,467,295	–
	814,066	1,404,636
Net change in cash during the period	(7,580)	236,843
Cash, beginning of period	345,950	811,584
Cash, end of period	338,370	1,048,427

1	Gross profit is defined as revenue, which is comprised of onboarding Welcome Kit revenue, ongoing engagement fees and success fees, less cost of sales, which is comprised of Welcome Kit costs, compensation expense for Inspirators and care specialists, genetic testing costs and the amortization of intangible assets. Gross margin percentage is calculated by dividing gross profit by total revenue for the defined period. Gross profit is considered by management to be an integral measure of financial performance and represents the amount of revenues retained by the Company after incurring direct costs. However, gross profit is not a recognized measure of profitability under IFRS. The Company defines Non-IFRS gross profit as gross profit plus amortization of intangible assets, for a true revenue less direct cost calculation and an "apples to apples" comparison vs. prior periods.
2	Adjusted operating expenses consist of all cash-based technology, sales and marketing and administrative expenses. Adjusted operating expense is not a measure of financial performance under IFRS and should not be considered a substitute for total operating expenses, which we believe to be the most directly comparable IFRS measure.
3	EBITDA stands for "earnings before interest, tax, depreciation and amortization". Although a commonly used financial metric, EBITDA is not a measure of financial performance under IFRS and should not be considered a substitute for loss from operations which we believe to be the most directly comparable IFRS measure.